Department of General Surgery Two, Shanxi Cancer Hospital, Shanxi Cancer Hospital of Shanxi Medical University, Zhigong Xin Street 3, 030013, Taiyuan City, Shanxi Province, China.
Wien Klin Wochenschr. 2023 Sep;135(17-18):472-477. doi: 10.1007/s00508-023-02155-x. Epub 2023 Apr 19.
Many diseases can mimic the symptoms of gastric cancer (GC). Therefore, misdiagnosis of GC is common. Our preliminary sequencing analysis revealed the altered expression of circSLIT2 in GC. In this study, we further explored the role of circSLIT2 in GC.
The research subjects included GC patients, patients with irritable bowel syndrome (IBS), patients with gastric ulcer (GU), patients with gastric tuberculosis (GT), patients with Crohn's disease (CD), and healthy controls (HC). Accumulation of circSLIT2 RNA in both tissue and plasma samples was determined with RT-qPCR. The diagnostic and prognostic values of circSLIT2 for GC were explored by performing ROC and survival curve analysis. The χ-test was applied for association analysis.
Increased circSLIT2 RNA accumulation was observed in GC tissues compared to non-tumor tissues. Compared to the HC group, increased plasma circSLIT2 RNA accumulation was only observed in the GC group, but not in the IBS, GU, GT, and CD groups. Plasma circSLIT2 showed a positive correlation with circSLIT2 in GC tissues but not circSLIT2 in non-tumor tissues. Using increased plasma circSLIT2 as a biomarker, GC patients were effectively separated from other disease groups and the HC group. Survival curve analysis revealed that most patients who died during the 5‑year follow-up had high levels of circSLIT2 accumulation in GC tissues and plasma. CircSLIT2 in plasma and GC tissue was only closely associated with distant tumor metastases, but not other clinical factors.
Increased circSLIT2 accumulation may serve as a novel diagnostic and prognostic biomarker for GC.
许多疾病的症状与胃癌（GC）相似，因此 GC 误诊较为常见。我们的初步测序分析显示 circSLIT2 在 GC 中的表达发生改变。在本研究中，我们进一步探讨了 circSLIT2 在 GC 中的作用。
研究对象包括 GC 患者、肠易激综合征（IBS）患者、胃溃疡（GU）患者、胃结核（GT）患者、克罗恩病（CD）患者和健康对照（HC）。采用 RT-qPCR 检测组织和血浆样本中 circSLIT2 RNA 的积累。通过 ROC 和生存曲线分析探讨 circSLIT2 对 GC 的诊断和预后价值。采用 χ2 检验进行关联分析。
GC 组织中 circSLIT2 RNA 积累增加，与非肿瘤组织相比。与 HC 组相比，仅在 GC 组中观察到血浆 circSLIT2 RNA 积累增加，而在 IBS、GU、GT 和 CD 组中未观察到。血浆 circSLIT2 与 GC 组织中的 circSLIT2 呈正相关，但与非肿瘤组织中的 circSLIT2 无相关性。使用增加的血浆 circSLIT2 作为生物标志物，可有效将 GC 患者与其他疾病组和 HC 组区分开。生存曲线分析显示，在 5 年随访期间死亡的大多数患者的 GC 组织和血浆中 circSLIT2 积累水平较高。血浆和 GC 组织中的 circSLIT2 仅与远处肿瘤转移密切相关，而与其他临床因素无关。
circSLIT2 积累增加可能成为 GC 的一种新型诊断和预后生物标志物。
